Immunotherapy after second surgery shows promise for tough head and neck cancers
NCT ID NCT03355560
First seen May 08, 2026 · Last updated May 08, 2026
Summary
This study tested the drug nivolumab in 39 people with head and neck cancer that returned after initial radiation or chemoradiation. All participants had surgery to remove the returning cancer, then received nivolumab to see if it was safe and could help control the disease. The main goal was to measure serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
UC Health
Cincinnati, Ohio, 45219, United States
Conditions
Explore the condition pages connected to this study.